Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 3/2015

01-03-2015

Biomarkers for Dysplastic Barrett’s: Ready for Prime Time?

Authors: Eleanor M. Gregson, Rebecca C. Fitzgerald

Published in: World Journal of Surgery | Issue 3/2015

Login to get access

Abstract

Background

There is need for the application of biomarkers in a clinical setting in order to improve patient care. Current surveillance methods are costly for health care systems and invasive for patients, and subjective methodology leads to frequent misdiagnosis. This review summarises the most advanced recent and relevant literature in the field of biomarker development in the context of Barrett’s esophagus and comments on their potential application. Studies included roughly correlate with Early Detection Research Network phases three and four.

Recent findings

A number of individual candidate and panels of biomarkers have been investigated recently. These include: gene-specific mutations such as loss of heterozygosity, copy number alterations (in particular aneuploidy) methylation panels, altered gene expression, and glycosylation assayed by lectin binding, as well as genetic and clonal diversity measures. Immunostaining for p53 is the only candidate biomarker deemed “ready for prime time.” This has been recommended for use clinically as an adjunct to histological diagnosis of dysplastic Barrett’s esophagus in the 2014 British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s esophagus.

Conclusions

Progress is being made but in many cases further prospective validation studies are required before clinical application can take place. Limitations to furthering these studies include the large patient cohorts required for prospective validation studies, costs associated with studies, and reproducibility of methods across laboratories. Continued research in this area is strongly recommended as, in the long run, biomarker application has the potential to significantly improve patient care.
Literature
1.
2.
3.
Su Z, Gay LJ, Strange A et al (2012) Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett’s esophagus. Nat Genet 44(10):1131–1136CrossRefPubMed
4.
Levine DM, Ek WE, Zhang R et al (2013) A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett’s esophagus. Nat Genet 45(12):1487–1493CrossRefPubMed
5.
Frankel A, Armour N, Nancarrow D et al (2014) Genome-wide analysis of esophageal adenocarcinoma yields specific copy number aberrations that correlate with prognosis. Genes Chromosom Cancer 53(4):324–338CrossRefPubMed
6.
Ek WE, Levine DM, D’Amato M et al (2013) Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett’s esophagus, and gastroesophageal reflux. J Natl Cancer Inst 105(22):1711–1718CrossRefPubMedCentralPubMed
7.
8.
Hvid-Jensen F, Pedersen L, Drewes AM et al (2011) Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med 365(15):1375–1383CrossRefPubMed
9.
Bhat S, Coleman HG, Yousef F et al (2011) Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst 103(13):1049–1057CrossRefPubMedCentralPubMed
10.
Sikkema M, de Jonge PJ, Steyerberg EW et al (2010) Risk of esophageal adenocarcinoma and mortality in patients with Barrett’s esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 8(3):235–244 quiz e32CrossRefPubMed
11.
Curvers WL, ten Kate FJ, Krishnadath KK et al (2010) Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am J Gastroenterol 105(7):1523–1530CrossRefPubMed
12.
Shaheen NJ, Sharma P, Overholt BF et al (2009) Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 360(22):2277–2288CrossRefPubMed
13.
Fitzgerald RC, di Pietro M, Ragunath K et al (2014) British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut 63(1):7–42CrossRefPubMed
14.
Spechler SJ, Sharma P, Souza RF et al (2011) American gastroenterological association technical review on the management of Barrett’s esophagus. Gastroenterology 140(3):e18–e52 quiz e13CrossRefPubMedCentralPubMed
15.
Fountoulakis A, Zafirellis KD, Dolan K et al (2004) Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br J Surg 91(8):997–1003CrossRefPubMed
16.
Wong T, Tian J, Nagar AB (2010) Barrett’s surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 123(5):462–467CrossRefPubMed
17.
Corley DA, Mehtani K, Quesenberry C et al (2013) Impact of endoscopic surveillance on mortality from Barrett’s esophagus-associated esophageal adenocarcinomas. Gastroenterology 145(2):312-9.e1CrossRefPubMed
18.
Gupta M, Iyer PG, Lutzke L et al (2013) Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett’s esophagus: results from a US Multicenter Consortium. Gastroenterology 145(1):79-86.e1CrossRefPubMedCentralPubMed
19.
Haidry RJ, Dunn JM, Butt MA et al (2013) Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett’s esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 145(1):87–95CrossRefPubMed
20.
Dulak AM, Stojanov P, Peng S et al (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45(5):478–486CrossRefPubMed
21.
Agrawal N, Jiao Y, Bettegowda C et al (2012) Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2(10):899–905CrossRefPubMedCentralPubMed
22.
Pepe MS, Etzioni R, Feng Z et al (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93(14):1054–1061CrossRefPubMed
23.
Reid BJ, Prevo LJ, Galipeau PC et al (2001) Predictors of progression in Barrett’s esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 96(10):2839–2848CrossRefPubMedCentralPubMed
24.
Reid BJ, Levine DS, Longton G et al (2000) Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol 95(7):1669–1676PubMedCentralPubMed
25.
Galipeau PC, Li X, Blount PL et al (2007) NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med 4(2):e67CrossRefPubMedCentralPubMed
26.
Shariff MK, Di Pietro M, Boerwinkel DF et al (2012) Time: a prospective study combining endoscopic trimodal imaging and molecular endpoints to improve risk stratification in Barrett’s esophagus. Digestive Disease Week; May 2012; San Diego. Gastroenterology 142:S427
27.
Bird-Lieberman EL, Dunn JM, Coleman HG et al (2012) Population-based study reveals new risk-stratification biomarker panel for Barrett’s esophagus. Gastroenterology 143(4):927-35 e3CrossRefPubMed
28.
Bird-Lieberman EL, Neves AA, Lao-Sirieix P et al (2012) Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett’s esophagus. Nat Med 18(2):315–321CrossRefPubMed
29.
Schulmann K, Sterian A, Berki A et al (2005) Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett’s-associated neoplastic progression and predicts progression risk. Oncogene 24(25):4138–4148CrossRefPubMed
30.
Jin Z, Cheng Y, Olaru A et al (2008) Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. Int J Cancer 123(10):2331–2336CrossRefPubMed
31.
Jin Z, Hamilton JP, Yang J et al (2008) Hypermethylation of the AKAP12 promoter is a biomarker of Barrett’s-associated esophageal neoplastic progression. Cancer Epidemiol Biomark Prev 17(1):111–117CrossRef
32.
Jin Z, Mori Y, Hamilton JP et al (2008) Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer 112(1):43–49CrossRefPubMed
33.
Jin Z, Mori Y, Yang J et al (2007) Hypermethylation of the nel-like 1 gene is a common and early event and is associated with poor prognosis in early-stage esophageal adenocarcinoma. Oncogene 26(43):6332–6340CrossRefPubMed
34.
Jin Z, Olaru A, Yang J et al (2007) Hypermethylation of tachykinin-1 is a potential biomarker in human esophageal cancer. Clin Cancer Res 13(21):6293–6300CrossRefPubMed
35.
Jin Z, Cheng Y, Gu W et al (2009) A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett’s esophagus. Cancer Res 69(10):4112–4115CrossRefPubMedCentralPubMed
36.
Alvi MA, Liu X, O’Donovan M et al (2013) DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res 19(4):878–888CrossRefPubMed
37.
Maley CC, Galipeau PC, Finley JC et al (2006) Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 38(4):468–473CrossRefPubMed
38.
Merlo LM, Shah NA, Li X et al (2010) A comprehensive survey of clonal diversity measures in Barrett’s esophagus as biomarkers of progression to esophageal adenocarcinoma. Cancer Prev Res (Phila) 3(11):1388–1397CrossRef
39.
40.
Li X, Galipeau PC, Paulson TG et al (2014) Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett’s esophagus. Cancer Prev Res (Phila) 7(1):114–127CrossRef
41.
Bani-Hani K, Martin IG, Hardie LJ et al (2000) Prospective study of cyclin D1 overexpression in Barrett’s esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst 92(16):1316–1321CrossRefPubMed
42.
Lao-Sirieix P, Lovat L, Fitzgerald RC (2007) Cyclin A immunocytology as a risk stratification tool for Barrett’s esophagus surveillance. Clin Cancer Res 13(2 Pt 1):659–665CrossRefPubMed
43.
Rygiel AM, Milano F, Ten Kate FJ et al (2008) Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia–dysplasia-adenocarcinoma sequence of Barrett’s esophagus. Cancer Epidemiol Biomark Prev 17(6):1380–1385CrossRef
44.
Paterson AL, O’Donovan M, Provenzano E et al (2013) Characterization of the timing and prevalence of receptor tyrosine kinase expression changes in oesophageal carcinogenesis. J Pathol 230(1):118–128CrossRefPubMed
45.
Rygiel AM, Milano F, Ten Kate FJ et al (2008) Assessment of chromosomal gains as compared to DNA content changes is more useful to detect dysplasia in Barrett’s esophagus brush cytology specimens. Genes Chromosom Cancer 47(5):396–404CrossRefPubMed
46.
Pacha A, Westra W et al (2012) A diagnostic DNA FISH biomarker assay identifies HGD or EAC in Barrett esophagus. Digestive Disease Week; May 2012; San Diego. Gastroenterology 142:S445
47.
Greenblatt MS, Bennett WP, Hollstein M et al (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54(18):4855–4878PubMed
48.
Kaye PV, Haider SA, James PD et al (2010) Novel staining pattern of p53 in Barrett’s dysplasia-the absent pattern. Histopathology 57(6):933–935CrossRefPubMed
49.
Weston AP, Banerjee SK, Sharma P et al (2001) p53 protein overexpression in low grade dysplasia (LGD) in Barrett’s esophagus: immunohistochemical marker predictive of progression. Am J Gastroenterol 96(5):1355–1362CrossRefPubMed
50.
Murray L, Sedo A, Scott M et al (2006) TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort. Gut 55(10):1390–1397CrossRefPubMedCentralPubMed
51.
Kastelein F, Biermann K, Steyerberg EW et al (2013) Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut 62(12):1676–1683CrossRefPubMed
52.
Kaye PV, Haider SA, Ilyas M et al (2009) Barrett’s dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 54(6):699–712CrossRefPubMed
53.
Li M, Anastassiades CP, Joshi B et al (2010) Affinity peptide for targeted detection of dysplasia in Barrett’s esophagus. Gastroenterology 139(5):1472–1480CrossRefPubMedCentralPubMed
54.
Kadri SR, Lao-Sirieix P, O’Donovan M et al (2010) Acceptability and accuracy of a non-endoscopic screening test for Barrett’s oesophagus in primary care: cohort study. BMJ 341:c4372CrossRefPubMedCentralPubMed
55.
Benaglia T, Sharples LD, Fitzgerald RC et al (2013) Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett’s esophagus. Gastroenterology 144(1):62-73.e6CrossRefPubMed
56.
Alvi MA, Liu XX, O’Donovan M et al (2013) DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett’s esophagus. Clin Cancer Res 19(4):878–888CrossRefPubMed
Metadata
Title
Biomarkers for Dysplastic Barrett’s: Ready for Prime Time?
Authors
Eleanor M. Gregson
Rebecca C. Fitzgerald
Publication date
01-03-2015
Publisher
Springer US
Published in
World Journal of Surgery / Issue 3/2015
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2640-x

Other articles of this Issue 3/2015

World Journal of Surgery 3/2015 Go to the issue

Invited Commentary

Barrett’s Oesophagus: A Tailored Strategy

Original Scientific Report

Rate of Pulmonary Metastasis Varies with Location of Rectal Cancer in the Patients Undergoing Curative Resection

Letter

Prospective Randomized Controlled Trial on the Use of Flexible Reinforced Laryngeal Mask Airway (LMA) during Total Thyroidectomy: Effects on Postoperative Laryngopharyngeal Symptoms: Reply

Invited Commentary

Antireflux Surgery for Dysplastic Barrett’s Esophagus

Original Scientific Report

Sagittal Abdominal Diameter is a Better Predictor than Body Mass Index for Duration of Laparoscopic Left Colectomy

Original Scientific Report

Pedestrian Injuries-Related Deaths: A Global Evaluation